the effect of amitriptyline in patients with pain and diarrhea predominant irritable bowel syndrome: a double-blind randomized controlled study
نویسندگان
چکیده
background: ibs is the most common disorder diagnosed by gastroenterologists, which is seen in approximately 40-50% of patients seeking care from a specialist. several randomized controlled trials, have assessed the therapeutic effect of anti-depressant drugs, but there is not enough evidence to prove their effectiveness. materials and methods: fifty cases meeting rome ii criteria for ibs with predominance of pain and diarrhea were included in this study. organic causes were ruled out by detailed history, physical examination, laboratory tests, small bowel transit and rectosigmoidoscopy. participants were then randomly assigned to receive either amitriptyline or placebo. subjects were followed using a simple symptom score system before, after 1 and 2 months of treatment. results: at the end of the 2nd month, amitriptyline showed more influence in reduction of flatulence, mucus passing and incomplete defication feeling, than placebo (p‹0.05). also, symptoms general improvement rate was 39% and 15% in amitriptyline and placebo groups respectively (p‹0.001).the rate of side-effects in the two groups did not have significant differences (p›0.05). conclusion: amitriptyline is an effective and well-tolerated treatment for pain and diarrhea predominant ibs.
منابع مشابه
Moxibustion treatment for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial
BACKGROUND Irritable bowel syndrome (IBS) is a worldwide disease with high morbidity. The effect of current treatment with Western medicine is not satisfactory. Although moxibustion treatment is widely used for gastrointestinal diseases, randomized controlled trials on the use of this treatment for IBS are limited. This study aims to evaluate the clinical efficacy and safety of moxibustion trea...
متن کاملA Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
We aimed to evaluate clinical symptoms in diarrhea predominant irritable bowel syndrome (IBS-D) receiving berberine hydrochloride in a randomized double-blind placebo-controlled clinical trial. Overall, 196 patients with IBS-D were recruited for this study; consequently, 132 patients randomized to receive daily 400 mg of berberine hydrochloride, delivered twice daily or placebo for 8 weeks foll...
متن کاملDouble-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents.
OBJECTIVES To determine the efficacy of amitriptyline (AMI) in treating irritable bowel syndrome (IBS) in adolescents. STUDY DESIGN Adolescents 12 to 18 years with newly diagnosed IBS were surveyed with a symptom checklist, pain rating scale, visual analog scale, and IBS quality of life (QOL) questionnaire. Subjects were randomized in a double-blinded fashion to receive AMI or placebo, and ag...
متن کاملthe effect of fluoxetine in patients with pain and constipation predominant irritable bowel syndrome
background: irritable bowel syndrome (ibs) is the most common disorder diagnosed by gastroenterologists seen in about 40-50% of patients seeking care from a specialist. ibs has been treated with selective serotonin reuptake inhibitors, but there is not enough evidence from controlled trials for their effectiveness. materials and methods: the aim of the study was to compare the effects of fluoxe...
متن کاملEffect of acupuncture on the pain of patients with acute low back pain: A randomized double-blind clinical trial study
Introduction: Low back pain is one of the most common causes of daily activity limitation and functional disabilities that affect a large number of people in the community. Due to the ineffectiveness of oral analgesics in relieving this type of pain and the need for their long-term use, which has its own side effects, the present study investigated the supplementary effect of acupuncture on pai...
متن کاملEluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
Eluxadoline is a novel drug approved for the management of diarrhea predominant irritable bowel syndrome (IBS-D). It has unique pharmacology and works on three different opioid receptors. Several Phase II and III clinical trials have demonstrated eluxadoline's efficacy in reducing symptoms related to IBS-D. Clinical trial results and postmarketing reports show a risk of pancreatitis in patients...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
گوارشجلد ۱۱، شماره ۳، صفحات ۱۳۹-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023